MedTrace Logo

PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)

NCT04974294 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2023-01-05

No results posted yet for this study

Summary

To determine the effect of PCV-13 and PPV-23 vaccination versus control on experimental pneumococcal colonisation of 2 clades of serotypes 3 and 6B at 1 month and 6 months post vaccination respectively, using the EHPC model.

Conditions

  • Streptococcus Pneumonia

Interventions

BIOLOGICAL

PPV23

random allocation 1:1:1 IM injection

BIOLOGICAL

PCV13

random allocation 1:1:1 IM injection

OTHER

Saline for injection

random allocation 1:1:1 IM injection

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Liverpool School of Tropical Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2023-07-31
Completion
2023-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974294 on ClinicalTrials.gov